Key clinical point: Adding metformin to EGFR-TKI therapy improved progression-free survival in patients with advanced lung adenocarcinoma.
Major finding: Median PFS was 13.1 months with metformin-EGFR-TKI combination therapy and 9.9 months with EGFR-TKI monotherapy (hazard ratio, 0.60; P = .03).
Study details: A phase 2 study of 139 patients with EGFR-mutated lung adenocarcinoma.
Disclosures: The study was funded by the National Council for Science and Technology in Mexico. The authors reported financial affiliations with AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, Pfizer, Roche, and several others.
Arrieta O et al. JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2553.